Antiapoptotic Activity of Alzheimer Abeta

阿尔茨海默病 Abeta 的抗凋亡活性

基本信息

  • 批准号:
    6631585
  • 负责人:
  • 金额:
    $ 18.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-06-01 至 2005-05-31
  • 项目状态:
    已结题

项目摘要

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is characterized by neuronal cell loss and the deposition of protein aggregates. These neuropathological parameters are correlated with the presence of numerous markers of oxidative stress in the cell bodies of neurons suggesting the involvement of oxidative mechanisms in neuronal cell loss and/or protein deposition. Although the sources of the reactive oxygen species (ROS) leading to this oxidative stress have not been clarified, the brain responds to this chronic oxidative challenge by upregulating antioxidant defense systems (eg. increasing SOD1 and glutathione peroxidase expression). We now have three lines of evidence indicating that the increased generation of Abeta in AD also may be a compensatory response to oxidative stress that prevents neuronal apoptosis. Firstly, we have determined from in vitro studies that Abeta has significant antioxidant (superoxide dismutase) activity, secondly, that nanomolar concentrations of Abeta block apoptosis of neurons following trophic factor withdrawal, and thirdly that the Abeta amyloid burden of the AD-affected brain is significantly negatively correlated with oxidative stress markers. In support of these findings, we find fewer oxidative modifications in amyloid deposits and neurofibrillary tangles compared with the cell bodies of the neurons of AD-affected brains. Together, these compelling data provide a plausible physiological explanation for the increased generation of Abeta in AD and following head trauma. We hypothesize that as the disease progresses, the chronic overproduction of hydrogen peroxide by neuronal cells, microglia and Abeta amyloid deposits may overwhelm the antioxidant defense systems of the aging brain with the end result that ROS promote the apoptotic demise. Thus, the novel aspect of our hypothesis is the recognition that Abeta generation may be a form of pleiotrophic antagonism, whereby Abeta may be physiologically purposive under "normal" conditions (i.e. moderately increased concentrations of superoxide and/or high reducing equivalents), but may promote neuronal cell death under abnormal conditions (i.e. high concentrations of superoxide and Abeta that lead to excess hydrogen peroxide/low reducing equivalents). The proposed studies will therefore examine the generation of Abeta as a compensatory mechanism to oxidative stress that is both antioxidant and anti-apoptotic in nature while testing whether overwhelming oxidative challenges promote apoptosis. We also will test whether oxidative stress induces neurons to re-enter the cell cycle as a mechanism leading to cell death.
阿尔茨海默病 (AD) 是一种使人衰弱的神经退行性疾病,其特征是神经元细胞损失和蛋白质聚集体沉积。这些神经病理学参数与神经元细胞体中多种氧化应激标志物的存在相关,表明氧化机制参与神经元细胞损失和/或蛋白质沉积。尽管导致这种氧化应激的活性氧 (ROS) 来源尚未明确,但大脑通过上调抗氧化防御系统(例如增加 SOD1 和谷胱甘肽过氧化物酶的表达)来应对这种慢性氧化挑战。我们现在有三方面的证据表明,AD 中 Abeta 生成的增加也可能是对氧化应激的一种代偿反应,可防止神经元凋亡。首先,我们通过体外研究确定 Abeta 具有显着的抗氧化(超氧化物歧化酶)活性,其次,纳摩尔浓度的 Abeta 可以阻止营养因子撤除后神经元的凋亡,第三,AD 影响的大脑的 Abeta 淀粉样蛋白负担是与氧化应激标志物显着负相关。为了支持这些发现,我们发现,与受 AD 影响的大脑神经元的细胞体相比,淀粉样蛋白沉积物和神经原纤维缠结中的氧化修饰较少。总之,这些令人信服的数据为 AD 和头部外伤后 Abeta 生成增加提供了合理的生理学解释。我们推测,随着疾病的进展,神经元细胞、小胶质细胞和 Abeta 淀粉样蛋白沉积物长期过量产生过氧化氢可能会压倒衰老大脑的抗氧化防御系统,最终导致 ROS 促进细胞凋亡。因此,我们假设的新颖之处在于认识到 Abeta 的产生可能是多效拮抗作用的一种形式,其中 Abeta 在“正常”条件下(即适度增加超氧化物浓度和/或高还原当量)可能具有生理目的,但也可能在异常条件下促进神经元细胞死亡(即高浓度的超氧化物和 Abeta 导致过量的过氧化氢/低还原当量)。因此,拟议的研究将检查 Abeta 的产生作为氧化应激的补偿机制,其本质上既具有抗氧化作用又具有抗凋亡作用,同时测试压倒性的氧化挑战是否会促进细胞凋亡。我们还将测试氧化应激是否会诱导神经元重新进入细胞周期,作为导致细胞死亡的机制。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Copper Induces Apoptosis of Neuroblastoma Cells Via Post-translational Regulation of the Expression of Bcl-2-family Proteins and the tx Mouse is a Better Model of Hepatic than Brain Cu Toxicity.
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0.1
  • 作者:
    Hsien W Chan;Tianbing Liu;G. Verdile;G. Bishop;Ryan J. Haasl;Mark A. Smith;George Perry;R. Martins;C. Atwood
  • 通讯作者:
    Hsien W Chan;Tianbing Liu;G. Verdile;G. Bishop;Ryan J. Haasl;Mark A. Smith;George Perry;R. Martins;C. Atwood
Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression.
  • DOI:
    10.1677/joe.1.07047
  • 发表时间:
    2006-12
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Andrea C. Wilson;M. S. Salamat;Ryan J. Haasl;K. Roche;A. Karande;S. V. Meethal;E. Terasawa;R. Bowen;C. Atwood;C. Atwood
  • 通讯作者:
    Andrea C. Wilson;M. S. Salamat;Ryan J. Haasl;K. Roche;A. Karande;S. V. Meethal;E. Terasawa;R. Bowen;C. Atwood;C. Atwood
Identification of a gonadotropin-releasing hormone receptor orthologue in Caenorhabditis elegans.
秀丽隐杆线虫中促性腺激素释放激素受体直系同源物的鉴定。
  • DOI:
    10.1186/1471-2148-6-103
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    VadakkadathMeethal,Sivan;Gallego,MiguelJ;Haasl,RyanJ;Petras3rd,StephenJ;Sgro,Jean-Yves;Atwood,CraigS
  • 通讯作者:
    Atwood,CraigS
Alzheimer's disease: the impact of age-related changes in reproductive hormones.
阿尔茨海默病:与年龄相关的生殖激素变化的影响。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig S Atwood其他文献

Craig S Atwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig S Atwood', 18)}}的其他基金

The LUCINDA Trial
露辛达审判
  • 批准号:
    10412901
  • 财政年份:
    2018
  • 资助金额:
    $ 18.62万
  • 项目类别:
The LUCINDA Trial
露辛达审判
  • 批准号:
    9988337
  • 财政年份:
    2018
  • 资助金额:
    $ 18.62万
  • 项目类别:
The LUCINDA Trial
露辛达审判
  • 批准号:
    9933921
  • 财政年份:
    2018
  • 资助金额:
    $ 18.62万
  • 项目类别:
The LUCINDA Trial
露辛达审判
  • 批准号:
    9597000
  • 财政年份:
    2018
  • 资助金额:
    $ 18.62万
  • 项目类别:
What Genes Experience:Environmental Moderators of Genetic Risk in MIDUS
基因经历了什么:MIDUS 遗传风险的环境调节因素
  • 批准号:
    8719412
  • 财政年份:
    2013
  • 资助金额:
    $ 18.62万
  • 项目类别:
Epistasis in Steroidogenic Genes in the Prediction of Alzheimer's Disease
类固醇生成基因的上位性在阿尔茨海默病的预测中的作用
  • 批准号:
    8440478
  • 财政年份:
    2012
  • 资助金额:
    $ 18.62万
  • 项目类别:
Epistasis in Steroidogenic Genes in the Prediction of Alzheimer's Disease
类固醇生成基因的上位性在阿尔茨海默病的预测中的作用
  • 批准号:
    8598792
  • 财政年份:
    2012
  • 资助金额:
    $ 18.62万
  • 项目类别:
Antiapoptotic Activity of Alzheimer Abeta
阿尔茨海默病 Abeta 的抗凋亡活性
  • 批准号:
    6509977
  • 财政年份:
    2001
  • 资助金额:
    $ 18.62万
  • 项目类别:
Antiapoptotic Activity of Alzheimer Abeta
阿尔茨海默病 Abeta 的抗凋亡活性
  • 批准号:
    6321451
  • 财政年份:
    2001
  • 资助金额:
    $ 18.62万
  • 项目类别:
REDOX METAL IONS AND NEURONAL PROTEIN DEPOSITION
氧化还原金属离子和神经元蛋白沉积
  • 批准号:
    2859119
  • 财政年份:
    1999
  • 资助金额:
    $ 18.62万
  • 项目类别:

相似国自然基金

远距离调控元件mbr对BCL2基因启动子表观遗传信息调控作用机制的研究
  • 批准号:
    90919051
  • 批准年份:
    2009
  • 资助金额:
    60.0 万元
  • 项目类别:
    重大研究计划

相似海外基金

Nanobodies for Dissecting the Structure and Function of Oligomeric BAX
用于剖析寡聚 BAX 结构和功能的纳米抗体
  • 批准号:
    10677287
  • 财政年份:
    2023
  • 资助金额:
    $ 18.62万
  • 项目类别:
Nitric Oxide-Soluble Guanylate Cyclase Pathway as a Target for Male Bladder Outlet Obstruction and Lower Urinary Tract Symptoms in Aging
一氧化氮可溶性鸟苷酸环化酶途径作为男性膀胱出口梗阻和衰老过程中下尿路症状的靶标
  • 批准号:
    10733864
  • 财政年份:
    2023
  • 资助金额:
    $ 18.62万
  • 项目类别:
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10537709
  • 财政年份:
    2022
  • 资助金额:
    $ 18.62万
  • 项目类别:
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
项目 III:工程化黑色素瘤和肾细胞癌中的免疫原性细胞死亡。
  • 批准号:
    10525194
  • 财政年份:
    2022
  • 资助金额:
    $ 18.62万
  • 项目类别:
Apoptotic Regulation and Neuroinflammation in Alzheimer's Disease
阿尔茨海默病的细胞凋亡调节和神经炎症
  • 批准号:
    10463986
  • 财政年份:
    2022
  • 资助金额:
    $ 18.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了